Clinical response after guselkumab treatment among adalimumab PASI 90 nonresponders: Results from the VOYAGE 1 and 2 trials

Objective: To evaluate the levels of response to guselkumab (GUS) among adalimumab (ADA) PASI 90 nonresponders in the VOYAGE 1 and VOYAGE 2 trials.

https://ift.tt/2vreaRe